1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
There are a handful of reasons to believe that Pantginis' estimate will become true, and there's one brand-new development for the biotech that's going to be particularly impactful in the near term. This key program is now advancing once again Regulators at the Food and Drug Administration (FDA) informed Iovance on March 4 that the company could proceed once more with its recently halted phase 2 clinical trial for treating non-small cell lung cancer with its candidate called LN-145. The move comes just weeks after the FDA granted approval for its candidate to treat advanced melanoma, which is now being commercialized under the trade name Amtagvi. Now, the company will be going into the rest of 2024 with the promise of ramping up its revenue from sales of a medicine for the first time, and its pipeline has a credible shot at delivering additional catalysts that were questionable during the clinical hold. Analysts on Wall Street think that Iovance will bring in an average of $167
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024GlobeNewswire
- Iovance Biotherapeutics to Present at Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
- With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 5/1/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- IOVA's page on the SEC website